Revance's board urges stockholders to vote in favor of Crown's acquisition offer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 31 2025
0mins
Tender Offer Details: Revance and Crown Laboratories are urging Revance stockholders to tender their shares at $3.65 each before the February 4, 2025 deadline, as this is the only available offer following Teoxane's withdrawal of its proposal.
Transaction Timeline: The transaction is expected to close by February 6, 2025, provided that more than 50% of shares are tendered and customary closing conditions are met, with no extension of the merger agreement's termination date planned by Crown.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
